Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Medical University of Vienna, Vienna, Austria.
Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.
J Cardiothorac Vasc Anesth. 2024 Feb;38(2):445-450. doi: 10.1053/j.jvca.2023.11.030. Epub 2023 Nov 25.
It remains unclear whether intraoperative lung-protective strategies can reduce the rate of respiratory complications after cardiac surgery, partly because low-risk patients have been studied in the past. The authors established a screening model to easily identify a high-risk group for severe pulmonary complications (ie, pneumonia or acute respiratory distress syndrome) that may be the ideal target population for the assessment of the potential benefits of such measures.
Retrospective observational trial.
Departments of cardiac surgery and cardiac anesthesia of a university hospital.
Consecutive patients undergoing cardiac surgery on cardiopulmonary bypass and subsequent treatment at a dedicated cardiosurgical intensive care unit between January 2019 and March 2021.
None.
Of the 2,572 patients undergoing surgery, 84 (3.3%) developed pneumonia/acute respiratory distress syndrome that significantly affected the outcome (ie, longer ventilatory support [66% vs 11%], higher reintubation rate [39% vs 3%]), prolonged length of intensive care unit [33 ± 36 vs 4 ± 10 days] and hospital stay [10 ± 15 vs 6 ± 7 days], and higher in-hospital [43% vs 9%] as well as 30-day [7% vs 3%] mortality). The screening model for severe pulmonary complications included left ventricular ejection fraction <52%, EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) >5.9, cardiopulmonary bypass time >123 minutes, left ventricular assist device or aortic repair surgery, and bronchodilatory therapy. A cutoff for the predicted risk of 2.5% showed optimal sensitivity and specificity, with an area under the receiver operating characteristic curve of 0.82.
The authors suggest that future research on intraoperative lung-protective measures focuses on this high-risk population, primarily aiming to mitigate severe forms of postoperative pulmonary dysfunction associated with poor outcomes and increased resource consumption.
目前仍不清楚术中肺保护策略是否能降低心脏手术后发生呼吸系统并发症的几率,部分原因是过去的研究纳入了低危患者。作者建立了一个筛选模型,以便能够轻易识别出发生严重肺部并发症(如肺炎或急性呼吸窘迫综合征)的高危人群,这些患者可能是评估此类措施潜在获益的理想目标人群。
回顾性观察性研究。
一所大学医院的心脏外科和心脏麻醉科。
2019 年 1 月至 2021 年 3 月期间在体外循环下行心脏手术并随后在专门的心脏外科重症监护病房接受治疗的连续患者。
无。
在接受手术的 2572 例患者中,有 84 例(3.3%)发生肺炎/急性呼吸窘迫综合征,显著影响了预后(即通气支持时间更长[66%比 11%]、再插管率更高[39%比 3%]),重症监护病房住院时间延长[33 ± 36 比 4 ± 10 天]和住院时间延长[10 ± 15 比 6 ± 7 天],院内[43%比 9%]和 30 天[7%比 3%]死亡率也更高。严重肺部并发症的筛选模型包括左心室射血分数<52%、欧洲心脏手术风险评估系统 II(EuroSCORE II)>5.9、体外循环时间>123 分钟、左心室辅助装置或主动脉修复手术以及支气管扩张治疗。预测风险为 2.5%的截断值显示出最佳的灵敏度和特异性,受试者工作特征曲线下面积为 0.82。
作者建议未来关于术中肺保护措施的研究聚焦于这一高危人群,主要目的是减轻与不良结局和增加资源消耗相关的术后严重肺部功能障碍。